Biotech Values

[rwwine]

Jbog,

I agree that expenditures are very high given the sales revenue. Perhaps my personal expectations were too lofty ($27.5 M) and should have considered differently.

PDUFA date for sBLA in CD will prove to be an interesting experience for us all as we watch this story unfold. I suspect we will see another sell off after the FDA approval (should it take place). Seemingly companies getting the FDA nod are getting hammered hard after the announcement. Perhaps the big investment firms are shorting the heck out of companies like RVNC? Not sure about much these days sir.